Virginia Arrazubi

1.3k total citations · 1 hit paper
48 papers, 641 citations indexed

About

Virginia Arrazubi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Virginia Arrazubi has authored 48 papers receiving a total of 641 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Virginia Arrazubi's work include Cancer Immunotherapy and Biomarkers (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Gastric Cancer Management and Outcomes (8 papers). Virginia Arrazubi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Gastric Cancer Management and Outcomes (8 papers). Virginia Arrazubi collaborates with scholars based in Spain, United States and France. Virginia Arrazubi's co-authors include María Alsina, Josep Tabernero, Marc Díez, Javier Suárez, Lucía Teijeira, Ruth Vera, Ruth Vera, Gemma Asín, Fernando Arias de la Vega and Juan Ignacio Arrarás and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Virginia Arrazubi

44 papers receiving 633 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current developments in gastric cancer: from molecular profiling to treatment strategy

2022 208 citations María Alsina, Virginia Arrazubi et al. profile →

Peers

Countries citing papers authored by Virginia Arrazubi

Since Specialization

Citations

This map shows the geographic impact of Virginia Arrazubi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Arrazubi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Arrazubi more than expected).

Fields of papers citing papers by Virginia Arrazubi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Arrazubi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Arrazubi. The network helps show where Virginia Arrazubi may publish in the future.

Co-authorship network of co-authors of Virginia Arrazubi

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Arrazubi. A scholar is included among the top collaborators of Virginia Arrazubi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Arrazubi. Virginia Arrazubi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oncological needs in transgender patients 2025 ·Clinical & Translational Oncology ·Francisco Ayala, David Martínez‐Ramos, Óscar Juan, (unknown), (unknown), David Páez, Virginia Arrazubi, (unknown)	0
2	Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma 2024 ·Scientific Reports ·Ibone Labiano, Ana E. Huerta, María Alsina, Hugo Arasanz, Natália Castro, (unknown), (unknown), (unknown), David Guerrero‐Setas, Ana Patiño‐García, Gorka Alkorta‐Aranburu, (unknown), Virginia Arrazubi, Elena Mata, David Gómez, A. Viúdez, Ruth Vera	4
3	Effects of an individualised exercise program in hospitalised older adults with cancer: A randomised clinical trial 2024 ·The journal of nutrition health & aging ·(unknown), Fabrício Zambom-Ferraresi, Adrienne Castillo, Mauricio R. Delgado, Arkaitz Galbete, Virginia Arrazubi, Idoia Morilla, (unknown), (unknown), Nicolás Martínez‐Velilla	0
4	TTCC-2022-01: Niraparib and dostarlimab in locally-advanced head and neck squamous cell carcinoma treated with (chemo) radiotherapy (RADIAN). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Virginia Arrazubi, Neus Basté, Irene Braña, Beatriz Cirauqui, Jon Cacicedo, J. Giralt, J. Marruecos, (unknown), (unknown), Valentín Navarro, Miguel Ángel Pujana, (unknown), (unknown), (unknown), (unknown), Alicia Lozano, Ricard Mesı́a	2
5	State of the scientific evidence and recommendations for the management of older patients with gastric cancer 2023 ·Journal of Geriatric Oncology ·(unknown), Paula Jiménez‐Fonseca, Juana María Cano, Virginia Arrazubi, Alberto Carmona‐Bayonas, (unknown), Ana Fernández Montés, Marta Martín-Richard, (unknown)	2
6	Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events 2023 ·Cancers ·Íñigo Les, (unknown), (unknown), (unknown), Lucía Teijeira, Virginia Arrazubi, (unknown), (unknown), (unknown), Grazyna Kochan, David Escors	46
7	Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck 2023 ·Cancers ·(unknown), Bryan Bennett, (unknown), Grant D. Stewart, Ana Medina, Petr Szturz, (unknown), Clara Castro, E. Gemmen, Ashley Lau, (unknown), Eric Winquist, Virginia Arrazubi, Desirée Hao, Audrey Cook, Joaquina Martínez-Galán, (unknown), (unknown), David Gutiérrez Abad, Robert Metcalf	2
8	O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study 2023 ·Annals of Oncology ·Elizabeth Smyth, M. Mauer, Chiara Alessandra Cella, Irit Ben‐Aharon, Guillaume Piessen, Lucjan Wyrwicz, (unknown), Tania Fleitas, Valérie Boige, M. Stahl, Uwe M. Martens, Radka Obermannová, Carlos Gómez-Martín, Peter Thuss‐Patience, Virginia Arrazubi, Antonio Avallone, Kai‐Keen Shiu, (unknown), (unknown), Florian Lordick	9
9	Tailored Prevention of Functional Decline through a Multicomponent Exercise Program in Hospitalized Oncogeriatric Patients: Study Protocol for a Randomized Clinical Trial 2023 ·The journal of nutrition health & aging ·Nicolás Martínez‐Velilla, Virginia Arrazubi, Fabrício Zambom-Ferraresi, (unknown), (unknown), Robinson Ramírez‐Vélez, (unknown), (unknown), (unknown), (unknown), Arkaitz Galbete, (unknown), (unknown), Míkel Izquierdo, Ruth Vera	1
10	Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma 2022 ·Cancers ·(unknown), A. Viúdez, Emilia Alors‐Pérez, Saioa Goñi, (unknown), Ismael Ghanem, Roberto Pazo-Cid, Jaime Feliú, (unknown), Carlos López, Virginia Arrazubi, Javier Gállego, (unknown), (unknown), Ruth Vera, Justo P. Castaño, Joaquín Fernández‐Irigoyen	3
11	P-53 A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma 2022 ·Annals of Oncology ·Geoffrey Y. Ku, Sarina A. Piha‐Paul, (unknown), Dong Yoon Oh, (unknown), (unknown), Sun Young Rha, Yujin Kang, M. Díez García, Tania Fleitas, Virginia Arrazubi, (unknown), (unknown)	4
12	Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma 2021 ·Frontiers in Medicine ·(unknown), Emilia Alors‐Pérez, (unknown), (unknown), (unknown), Saioa Goñi, José C. Reyes, María Ceballos-Chávez, (unknown), Marina Sánchez‐Frías, Enrique Santamaría, (unknown), Álvaro Arjona‐Sánchez, Virginia Arrazubi, (unknown), Ruth Vera, Joaquín Fernández‐Irigoyen, Justo P. Castaño, A. Viúdez	0
13	ASO Author Reflections: Circulating Tumor Cell Count is a Prognostic Factor in Patients with Resected Colorectal Cancer Liver Metastases 2019 ·Annals of Surgical Oncology ·Virginia Arrazubi	1
14	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer 2018 ·Journal of Cancer ·(unknown), Manuel Hidalgo, Rafael Álvarez, Virginia Arrazubi, Joaquina Martínez-Galán, Mercedes Salgado, Teresa Macarulla, Alfredo Carrato	28
15	Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors 2017 ·Reumatología Clínica ·Pascuala Garcı́a-Martı́nez, (unknown), Virginia Arrazubi, María Ángeles Sala, (unknown), (unknown), (unknown), (unknown)	3
16	SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016) 2016 ·Clinical & Translational Oncology ·Marta Martín-Richard, Robert Díaz Beveridge, Virginia Arrazubi, María Alsina, (unknown), Ana Custodio, (unknown), (unknown), (unknown), Fernando Rivera	20
17	Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy 2012 ·Colorectal Disease ·Virginia Arrazubi, Javier Suárez, D. Guerrero, (unknown), A. Viúdez, F. Árias, E Balén, Ruth Vera	9
18	Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial 2011 ·Annals of Oncology ·Fernando Arias de la Vega, Jorge Contreras, Manuel de las Heras, Alejandro de la Torre, Virginia Arrazubi, (unknown), I. Prieto, José Á. García-Sáenz, Jesús Romero, Felipe A. Calvo	11
19	The EORTC quality of life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients 2011 ·Clinical & Translational Oncology ·Juan Ignacio Arrarás, Javier Suárez, Fernando Arias de la Vega, Ruth Vera, Gemma Asín, Virginia Arrazubi, M. Rico, Lucía Teijeira, (unknown)	52
20	New drug development in digestive neuroendocrine tumors 2007 ·Annals of Oncology ·Ignacio Durán, Ramón Salazar, Oriol Casanovas, Virginia Arrazubi, Eduardo Vilar, Lillian L. Siu, James C. Yao, Josep Tabernero	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact